J. Cruz-Hernández

Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

C. García-Girón, R. Hitt, A. Ocaña, 2020, Clinical and Translational Oncology.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

C. García-Girón, R. Hitt, C. Jara-Sánchez, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC).

R. Hitt, H. Cortés-Funes, A. Irigoyen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Prospective Randomized Trial of Continuous Infusion 5‐Fluorouracil (5‐FU) Versus 5‐FU Plus Cisplatin in Patients with Advanced Colorectal Cancer A Trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.)

A. Carrato, C. Balañà, M. Martín, 1992, American journal of clinical oncology.

Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC).

C. García-Girón, R. Hitt, H. Cortés-Funes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients

J. García, D. Olmos, I. Misiewicz-Krzemińska, 2017, Clinical and Translational Oncology.

Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer

B. Győrffy, A. Pandiella, P. Pérez-Segura, 2021, Frontiers in Oncology.

A phase II study of weekly 48 hours infusion with high-dose Fluorouracil (FU) in colorectal cancer

A. Carrato, A. Tres, A. Antón, 1994 .

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

R. Hitt, J. García-Saenz, H. Cortés-Funes, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical practice evaluation of opioids induced constipation management in patients with cancer: The EIO-50 project

A. Carrato, P. Gascón, J. García-Foncillas, 2019 .

Metastatic prostate cancer with a normal prostate-specific antigen level

J. Cruz-Hernández, Isabel Ruiz-Martín, César A. Rodríquez-Sánchez, 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.

J. Fernández-Mateos, M. Taberna, A. Lozano, 2016, Oral oncology.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

C. García-Girón, R. Hitt, C. Jara-Sánchez, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

A. Carrato, R. López-López, E. Díaz-Rubio, 2014, Clinical and Translational Oncology.

Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population

T. Dilla, J. Sacristán, L. Lizán, 2015 .

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

R. Hitt, J. García-Saenz, A. Irigoyen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.